Jennifer L Holter Chakrabarty
Overview
Explore the profile of Jennifer L Holter Chakrabarty including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
51
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Magome T, Froelich J, Takahashi Y, Arentsen L, Holtan S, Verneris M, et al.
Int J Radiat Oncol Biol Phys
. 2016 Sep;
96(3):679-87.
PMID: 27681765
Purpose: To develop an imaging method to characterize and map marrow composition in the entire skeletal system, and to simulate differential targeted marrow irradiation based on marrow composition. Methods And...
2.
Wilke C, Holtan S, Sharkey L, DeFor T, Arora M, Premakanthan P, et al.
Radiother Oncol
. 2015 Dec;
118(1):65-71.
PMID: 26653357
Background And Purpose: Total body irradiation (TBI) is a common component of hematopoietic cell transplantation (HCT) conditioning regimens. Preclinical studies suggest prolonged bone marrow (BM) injury after TBI could contribute...
3.
Khawandanah M, Weiss S, Cherry M, Maymani H, Selby G, Aster R, et al.
Transfusion
. 2014 Sep;
55(3):657-60.
PMID: 25208591
Background: Evans syndrome is a rare condition manifested by combined autoimmune hemolytic anemia (AIHA) and thrombocytopenia or neutropenia. It is often associated with other autoimmune disorders, immunodeficiencies, and non-Hodgkin's lymphoma....
4.
Holter Chakrabarty J, Rubinger M, Le-Rademacher J, Wang H, Grigg A, Selby G, et al.
Biol Blood Marrow Transplant
. 2014 Apr;
20(7):1021-5.
PMID: 24691221
To identify favored choice of transplantation in patients with acute promyelocytic leukemia (APL) in second complete remission, we studied 294 patients with APL in second complete remission (CR2) receiving allogeneic...